Japanese Medical Product Manufacturer Pioneers Oral Bisphosphonate Jelly

Many orthopedic experts and pharmaceutical specialists believe that bisphosphonates, a medicine class that involves Merck’s Fosamax, is a profitable venture even though several side effects are being allegedly linked to them. In this case, a pharmaceutical company in Japan, Teijin Pharma Ltd., has published a press statement announcing government approval of its 35mg Bonalon Jelly on August 16, 2012. The company affirms that the pharmaceutical formulation is an improved generic of alendronate medicine compared with the 5mg tablet of Fosamax brand.

The jelly version promises various advantages from the older tablet variants of alendronate sodium hydrate. Medical jellies are easier to identify and may be easily swallowed compared with  the most orthopedic medicine available in the market. It is important for bone medicines to be distinctive, especially for a bisphosphate, since it should be medicated at least 30 minutes before or after taking any other type of medicine. Bonalon Jelly is also prescribed once a week in 35mg jelly which is less a hassle to users compared with a daily prescription.

Teijin stated that a decade of medical study has indicated how alendronate came to be safer based on a few months studies conducted in Japan and China. Both studies have reflected controversial allegations of adverse effects caused by the prescription.

Patients having orthopedic problems should not assume from the affirmation announcement on the recent approval of similar Fosamax generic. It is strongly suggested that they ask for a doctor’s referral regarding any advice of dosage updates. To know more about these issues, read Japanese Pharmaceutical Company Creates First Oral Jelly Bisphosphonate.